Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Video of James Januzzi explaining the results of a new diabetic cardiomyopathy treatment in ACC 2024 late-breaking ARISE-HF trial. #ACC #ACC24 #ACC2024

Diabetic cardiomyopathy treatment shows promise in ARISE-HF

James Januzzi Jr., MD, said the treatment's overall impact was neutral, but he and his team saw "a very clear and encouraging signal."

Sex, energy drinks and vaccines among the many topics planned for preventive cardiology conference

The three-day event will include sessions about sexual activity among heart patients, depression, energy drinks, stimulants, vaccines and more. The festivities begin Thursday, April 25, in Greece.

Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment

AskBio, acquired by Bayer for more than $2 billion in 2020, is enrolling patients for a new clinical trial focused on the therapy's effectiveness in adult patients with non-ischemic cardiomyopathy and heart failure.

FDA grants fast track designation to new drug for Friedreich's ataxia cardiomyopathy

The new gene therapy candidate is now one step closer to being approved by the FDA.

PHOTO GALLERY: Highlights from ACC.24 in Atlanta

ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement.

FDA grants anticoagulant its orphan drug designation for treating patients with implanted devices

The anticoagulant was originally developed for patients with end-stage renal disease and atrial fibrillation.

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

healthcare value value-based care money dollar

Novo Nordisk to acquire biotech company working on new heart failure drug for $1.1B

Cardior Pharmaceuticals in Germany has been developing a new compound it says can “halt and partially reverse cellular pathology” in heart failure patients.

Pharmaceutics

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes